Loading company…
Polymed Biopharmaceuticals develops drugs for tumors and autoimmune diseases.
Founded in 2018 in Hangzhou, Polymed Biopharmaceuticals researches drugs for tumors and autoimmune diseases, including PROTAC technology and protease inhibitors. In October 2025, it raised pre-Series A++ funding from Jiale Capital to support clinical development of its pipeline, with a focus on PROTAC drugs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in